Table 4.

Spearman’s correlation analysis evaluating the association between glucose metabolism index and aggressiveness of DTC in all patients (TNM staging-T, number of metastatic lymph nodes and capsule invasion).

	TNM staging-T		Number of metastatic lymph nodes
	r	P	r	P
Blood glucose
0 h	−0.051	0.451	0.079	0.226
1 h	0.107	0.115	−0.106	0.103
2 h	0.105	0.121	0.045	0.489
3 h	0.106	0.117	0.152	0.019
Insulin
0 h	0.097	0.152	0.034	0.600
1 h	0.110	0.106	−0.157	0.015
2 h	0.138	0.041	−0.107	0.101
3 h	0.175	0.010	−0.000	0.999
C-peptide
0 h	0.069	0.312	0.124	0.056
1 h	0.082	0.229	−0.211	0.001
2 h	0.137	0.042	−0.176	0.007
3 h	0.198	0.003	−0.049	0.450
HOMA-β	0.095	0.161	0.042	0.521
HOMA-IR	0.091	0.178	0.037	0.572
ISI	−0.170	0.012	0.073	0.261
CSI	−0.163	0.016	0.058	0.376
AUC of insulin	0.146	0.031	−0.111	0.087
AUC of C-peptide	0.148	0.029	−0.184	0.004
Delayed peak of insulin secretion	0.093	0.169	−0.014	0.843

DTC, differentiated thyroid carcinoma; HOMA-β, homeostasis model assessment of β cell; HOMA-IR, homeostasis model assessment of insulin resistance; ISI, insulin sensitivity index; CSI, C-peptide sensitivity index; AUC, area under curve. Data for Spearman’s correlation analysis was adjusted for sex, age, body weight, height, BMI, SBP, DBP, history of DM, duration of DM, smoking, drinking, HbA1c, TG, TC, LDL-c, HDL-c, uric acid, TSH, Tg, TgAb.